Active, not recruitingPhase 2NCT06015841
A Study to Evaluate the Effects of ACI-7104.056 in Patients With Early Stages of Parkinson's Disease
Studying Young-onset Parkinson disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AC Immune SA
- Principal Investigator
- Daniela Berg, Prof.Klinik für Neurologie, UKSH Campus Kiel, Germany
- Intervention
- Placebo(biological)
- Enrollment
- 150 target
- Eligibility
- 40-75 years · All sexes
- Timeline
- 2023 – 2028
Study locations (12)
- Katholisches Klinikum Bochum GmbH, Bochum, Germany
- Paracelsus-Kliniken Deutschland GmbH & Co. KGaA, Kassel, Germany
- University Medical Centre Schleswig-Holstein, Kiel, Germany
- Hospital De La Santa Creu I Sant Pau, Barcelona, Spain
- Hospital Universitari Vall D Hebron, Barcelona, Spain
- Policlinica Gipuzkoa, Donostia / San Sebastian, Spain
- Hospital Universitario De La Princesa, Madrid, Spain
- Hospital Universitario Puerta De Hierro De Majadahonda, Majadahonda, Spain
- Hospital Universitario Quironsalud Madrid, Pozuelo de Alarcón, Spain
- King's College Hospital NHS Foundation Trust, London, United Kingdom
- Re:Cognition Health Limited, London, United Kingdom
- Northern Care Alliance NHS Foundation Trust, Salford, United Kingdom
Collaborators
ICON Clinical Research
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06015841 on ClinicalTrials.govOther trials for Young-onset Parkinson disease
Additional recruiting or active studies for the same condition.